Medicamen Organics (NSE:MEDIORG) Asset Turnover: 0.09 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MEDIORG Medicamen Organics Ltd NSE:MEDIORG
21 GF Score
Price ₹24.00
! 11 Warning Signs
View Full Analysis

What is Medicamen Organics Asset Turnover?

Medicamen Organics NSE:MEDIORG +4.80% 21 Asset Turnover is 0.09 as of Mar. 2026. GuruFocus rates NSE:MEDIORG with a GF Score™ of 21/100. The stock has 11 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Medicamen Organics's Revenue for the six months ended in Mar. 2026 was ₹47.78 Mil. Medicamen Organics's Total Assets for the quarter that ended in Mar. 2026 was ₹554.18 Mil. Therefore, Medicamen Organics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.09.

Asset Turnover is linked to ROE % through Du Pont Formula. Medicamen Organics's annualized ROE % for the quarter that ended in Mar. 2026 was -41.17%. It is also linked to ROA % through Du Pont Formula. Medicamen Organics's annualized ROA % for the quarter that ended in Mar. 2026 was -21.86%.


Medicamen Organics  (NSE:MEDIORG) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Medicamen Organics's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-121.148/294.2825
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-121.148 / 95.56)*(95.56 / 554.181)*(554.181/ 294.2825)
=Net Margin %*Asset Turnover*Equity Multiplier
=-126.78 %*0.1724*1.8832
=ROA %*Equity Multiplier
=-21.86 %*1.8832
=-41.17 %

Note: The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Medicamen Organics's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-121.148/554.181
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-121.148 / 95.56)*(95.56 / 554.181)
=Net Margin %*Asset Turnover
=-126.78 %*0.1724
=-21.86 %

Note: The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Medicamen Organics Asset Turnover Related Terms


Medicamen Organics Asset Turnover Historical Data

* Premium members only.

The historical data trend for Medicamen Organics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicamen Organics Asset Turnover Chart

Medicamen Organics Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Asset Turnover
Get a 7-Day Free Trial 0.78 0.74 0.71 0.78 0.41

Medicamen Organics Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Mar25 Mar26
Asset Turnover Get a 7-Day Free Trial 0.00 0.34 0.38 0.44 0.09

NSE:MEDIORG vs ZTS, UTHR: Asset Turnover Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Organics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicamen Organics Asset Turnover vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicamen Organics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Medicamen Organics's Asset Turnover falls into.


NSE:MEDIORG
21GF Score
Medicamen Organics Ltd NSE:MEDIORG
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicamen Organics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Medicamen Organics's Asset Turnover for the fiscal year that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2026 )/( (Total Assets (A: Mar. 2025 )+Total Assets (A: Mar. 2026 ))/ count )
=226.303/( (592.074+516.288)/ 2 )
=226.303/554.181
=0.41

Medicamen Organics's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Mar. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=47.78/( (592.074+516.288)/ 2 )
=47.78/554.181
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.09 mean?
Medicamen Organics (NSE:MEDIORG) has a Asset Turnover of 0.09 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Medicamen Organics and its competitors.
Is Medicamen Organics' Asset Turnover too high?
Medicamen Organics' current Asset Turnover is 0.09. Overall, Medicamen Organics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Medicamen Organics' Asset Turnover compare to ZTS and UTHR?
Medicamen Organics' Asset Turnover of 0.09 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Drug Manufacturers company?
A good Asset Turnover depends on the Drug Manufacturers industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Medicamen Organics and its competitors. Medicamen Organics's current Asset Turnover is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Organics stock overvalued right now?
Medicamen Organics (NSE:MEDIORG) has a current Asset Turnover of 0.09. The current Asset Turnover is 0.09. Medicamen Organics' overall GF Score™ is 21/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Medicamen Organics (NSE:MEDIORG), the current Asset Turnover is 0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicamen Organics Business Description

Address Ashok Vihar Phase II, 10, Community Center No. 2, New Delhi, IND, 110052
Medicamen Organics Ltd develops, manufactures, and distributes a wide range of pharmaceutical dosage forms, including Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders. The company operates two WHO Good Manufacturing Practice certified facilities in India, producing products for both domestic and international clients. It provides contract manufacturing and loan license services to various pharmaceutical companies and exports to several countries across Africa, CIS, and South Asia. The principal source of revenue is through the manufacturing, export, and contract services focused on generic and branded pharmaceutical formulations.
21GF Score

Get the complete analysis for NSE:MEDIORG

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹24.00
Price